# XENSE 

First Meta CT in the World, 
Transforming Healthcare Delivery  


## Elevator pitch
XENSE is bringing a Better Future by being the 1st In the World to provide uTomo, compact CT and X-ray Imaging ( can be less than 1 degree movement) without performance compromises and ultralow radiation and to replace traditional 2D X-ray and CT technology for diagnostics, intervention, surveillance and monitoring.

- Canonical URL: https://wefunder.com/xense
- Entity ID: wefunder:company:111299
- Last updated: 2026-06-10T05:00:45Z
- Generated at: 2026-06-10T22:44:41Z

## Quick facts
- Platform Imaging Technology - Planning to Disrupt the $18B Medical Imaging Industry.
- Minimize Time to Diagnosis, Treatment & Wellness
- X-ray: the Most Adopted Diagnostic & Intervention Imaging Modality & Central to Healthcare Delivery.
- IMAGE LESS. LIVE BETTER!
- Join the XENSE Investor Family to Bring uTomo / Meta CT Faster to Your Nearest clinic.
- Our A+ Team & Investors are Experienced & Passionate 40+ Members Who Share the Same Vision & Values.
- Large Patent Portfolio: 50+, First One Filed Has Already Been Granted by the US Patent Office.

## Active fundraises
- wefunder:fundraise:60104: 4(a)(6) successful (USD)
- wefunder:fundraise:60371: 4(a)(6) successful (USD)

## Story
XENSE on CNBC, Advancements TV by Ted Danson, AMAZON, Season 6, Episode 2

## FAQ
1. **Can you please release relevant financial statements?**
   - Financials will be released when Form C is officially filed by the team at Wefunder. Will let you know as soon as we are able. Thanks!
2. **what kind of data you have on vascular accident ?**
   - Richard, We do not have any clinical data yet, we are fund raising so that we can do imaging on animal models of vascular accident /human studies. Traditional CT has the scatter interference problem, typically ~5% or a lot more, sometimes 20%, or in some cases, 65% or higher SPR ( scatter to primary x ray ratio) this is with antiscatter grid and collimator ( Fig.6-9 https://www.tandfonline.com/doi/full/10.1080/00223131.2016.1236709). Please keep in mind that a 3D reconstruction require hundre...
3. **With a companies like Nanox and Butterfly (“medtech moonshot” comps) both trading at only ~$400m enterprise value… What is the basis behind a $200m mark this early on? Both are are much further along re production capacity / FDA and have a strong B/S and big backers.**
   - Would like to ask you or anyone in the future who is going to post here in COMPANY FAQ to 1. Share your real identity. 2. Make sure when there is a question, the data presented in the content of the question are facts and verified before posting. Thank you and regards Ying
4. **Hello, do you have a working prototype, how does your technology compare or contrast to Nanox & Butterfly Network & do you have any direct competitors? . Hello Ying, thank you for answering my questions. Your instincts are correct. You gave me info I wanted. The analog...**
   - Hi, John, Thanks for asking. We will disclose exactly where we are regarding the prototype stage, ( typically there are alpha, beta and pilot prototypes ), once there is NDA signed if you are interested. we aim to submit to FDA at the end of year ( estimate) . This is a public forum, and this is a IP sensitive product / technology. Hope that you understand. Direct competitors: we are in the area of x -ray / CT imaging, so any manufacturer of such device is a potential competitor. Analogy woul...
5. **Is it fair to say that your valuation is based, in part, on your patent portfolio? If so, can you share more regarding your awarded patent and filed applications? I understand this is sensitive information to share in a public forum. 1) For your awarded patent, who is the owne...**
   - Hi, Jason. Thank you for asking. Correct, part of the valuation is based on patent portfolio. The other parts are the know how and product engineering, team ( it is not a small effort to pull together a team of people who share the same vision and value, and focused on making the company a success), and trademarks which we have "Meta", "X" ( all filed prior to facebook changed to Meta; Binance, its cryto market place as "X-meta", and first crypto coin named "Meta I", Twitter ( Elon Musk) now ...

## Team
- Ying Zhao (CEO and Founder)
- Sean Lavine (Head of Medical Affairs, Investor, Neurosurgeon )
- Alan Bliss (Director of Hardware & Electrical Engineering)
- Justin Shafa (Neuroradiologist,&  Investor )
- Sanjit Tewari, MD (Nuclear Med & Intervention Radiologist, Investor)

## Q&A
- Q: Hi Ying, I really like what I'm reading, and I'd love to see you hit $1M. But I'm brought up short by the high minimum investment amount. Many small investors simply cannot afford to put so many eggs into one basket (as they say). This $500 minimum is leaving a lot of us small investors out in the cold, so to speak. Would you please consider lowering it to a more inclusive and inviting amount like $200 or $250 at the most? Thanks for your consideration.
  - A: Hi, Kim, Thank you very much for your kind note. Sure. understand where you are coming from. Initially, we planned to set the minimum amount at $100. However, we have been advised to set at the current minimum due to a set of factors, some of it has to do with marketing costs for the campaign to reach potential investors and that the minimum needs to be above a threshold to ensure there is not a loss. Changing is also complicated, as once it is set at $500, if we decide to change, then expect that we can not really change it without additional amendment paperwork for SEC and all investor thus far may need to reconfirm their investment again, which can be a process. So all factors considered, we are at this current minimum. Hope that you understand. Thanks for bringing this up as a topic of discussion as we are sure some may also have the same question, Best, Ying
- Q: Is it fair to say that your valuation is based, in part, on your patent portfolio? If so, can you share more regarding your awarded patent and filed applications? I understand this is sensitive information to share in a public forum. 1) For your awarded patent, who is the owner? If not XENSE, is there a licensing agreement in place? What are the terms? 2) What claims do you have in the awarded patent? (That information should be publicly available.) 3) Your deck mentions 40+ patent applications. How many are unique utility patent applications filed with the USPTO? 4) What claims are you seeking in these applications? I realize the fourth question is the one that’s likely most sensitive. I am trying to assess how many of those 40+ applications are viable; i.e. how many are not old provisional applications, or duplicates filed in multiple countries, etc.
  - A: Hi, Jason. Thank you for asking. Correct, part of the valuation is based on patent portfolio. The other parts are the know how and product engineering, team ( it is not a small effort to pull together a team of people who share the same vision and value, and focused on making the company a success), and trademarks which we have "Meta", "X" ( all filed prior to facebook changed to Meta; Binance, its cryto market place as "X-meta", and first crypto coin named "Meta I", Twitter ( Elon Musk) now designated a product name as "X" ) and "XENSE" and domain names including MetaCT.com. (We have these trademarks for the markets which are relevant to our business and others may have rights in the area which they are focusing on) 1)XENSE has exclusive licenses for Human Health applications from the IP holding company. The IP holding company is owned by early investors such as seed and preSeed Investors and the founder. The Human Health market is the largest market, = >20 x or 10 x more than other markets, such as security or industrial applications, based on our research) . Terms are exclusive licensing for "Human Health" without any royalties paid to the IP holding company. There are a number of patents, but the core patent is on "x ray tomography", which details most of core technologies of the novel 3D CT configuration, we trade marked "uTomo" to name the new CT technology, which is described here: WO2019183002 - X-RAY TOMOGRAPHY patentscope.wipo.int…?docId=WO2019183002 The other patents are additional implementations and extension of the aforementioned patent. 2) Rather than speaking of specific claims as there are simply too many, we can summarize some of the key points of uTomo (TM) here i) S2DSR ( TM) - scatter removal down to 1% SPR ( Scatter to Primary Ratio), which allows high resolution x-ray imaging for quantitative 2D and 3D imaging whereas typically general x ray and CT have SPR of greater than 5% or can be as high as 80% as you can see from some of the articles we have attached in the earlier conversation. ii) Color Fluoro (TM) - Quantitative material separation imaging method in 2D and 3D, which has not previously been done well before, which allows for fast tracking and material separation in fluoroscopy in surgical guidance both in 2D and 3D. iii) nMatrix (TM) - Novel 3D tomographic imaging method which enables tomographic imaging at as small as 1 degree movement. The result of these is to enable advanced imaging to provide a high performance - ultralow radiation, high resolution and compact CT system for large dimensions ( for human, for example), previously not possible. All of the technologies are important in making a commercial unit to work and to provide a multiple modality system, which is not just another piece of capital equipment added to the collections of x ray imaging systems a hospital/clinics can own, but have the potential to replace every type of modality with equivalent or better performance. 3) good question - currently 4. which is already a lot more than most high tech startups at this stage or at least equivalent if you track recent medical device as well as medical imaging companies. And we are filing more as we speak. And please keep in mind most of them are recent and therefore will have 20 years validity. To put this in perspective, for many medical imaging companies by the time they get to this stage, they have either one or two recently filed patents which typically not granted yet, or have a number of granted patents already halfway into its life cycle as it may take years to have a complete set of IP for a product. So our patents are optimized to have a long life cycle while they are being commercialized. 4) Key claims are described in the patent above. Provisional patents: we have filed so far are ~50 patents, 5 unique USPTO patents and the rest of for different countries. The number excludes provisional patents. Hope that this is sufficient to get you started. X-ray is a widely adopted core modality. We are providing a new platform technology, which we believe will transform x-ray imaging / advanced medical imaging and bring the entire medical imaging field and healthcare delivery for general public into a new era. Please let us know if you have additional questions and welcome and appreciate any suggestions regarding product features and preferences from a user / patient perspective if you any. Thank you and best regards, -Ying
  - A: In case you are asking about the valuation rationale: to our knowledge, typically the valuation is directly proportional to the addressable target market of IP portfolio and the valuation of comparable companies in medical imaging and medical device industries at the similar stage. Based on the history data on the fund raise for the same development stage, the fact that we are the first mover and the most recent fund raising cases of selected medical device companies in ultrasound, x ray imaging, endoscope companies, the valuation is set typically between ~ $30 -60 million per $1 billion addressable market ( based on our study) , At this stage of funding ( Pre Series A- Series A), therefore, based on projected market size of estimated $26 billion for 2026, the valuation is estimated to be between $600 million to $1.8 billion ( based on information from pitchbook, crunchbase and SEC and our study). The reason for a higher valuation for early stage medical device and biopharma companies may partly be that there needs to be a large amount of funding to get through regulatory requirements for FDA approval and related certifications in the US and worldwide, for commercialization, mass production and additional costs involved in satisfying manufacturing standards for medical devices. The valuation also needs to be there so that sufficient funding can be raised to support a new company to effectively operate. In general $20 - 30 million of funding for a company providing this type of products may not be sufficient to operate in a global scale. Much more is needed, for example, between $100 million - $300 million. On the other hand, the barrier of entry tends to be fairly high. In addition, medical device and medical imaging markets are heavily regulated, patents are typically taken seriously or more seriously than some of the other markets, to our knowledge. Partly may be that in regulatory submissions, details of methods and apparatus of the device have to be described/disclosed to provide rationale for the efficacy of the product and related safety risks involved for the essential performance.
- Q: Can you please release relevant financial statements?
  - A: Financials will be released when Form C is officially filed by the team at Wefunder. Will let you know as soon as we are able. Thanks!
  - A: Hi, Andrew, Financial statements are released. Thank you for your patience! Best, -Ying
- Q: Any updates recently?
  - A: Thank you, Mirko, Did not see your msg until now. Making progress with product development and fund raising. over 20 patents have been awarded. Will keep you posted as we make more progress. Thank you again for checking in, Best regards -Ying
- Q: I am trying to understand the functional/operational benefits of the device/system. I get the idea of reduced cost and radiation exposure. I am an Emergency Physician who works both in suburban and another location in suburban/rural environments (some of the rural spots are 2 hours by driving from the hospital). I use plain film, fluoro and CT modalities a lot. If there is someone who could speak with me (of course, protecting your IP, that is understandable), this would be wonderful. I can think of many use cases that lead to the specialists who present in your marketing presentation. I may be helpful with clinical trials as I have participated in some before. Neal Handly MD
  - A: Hi, Dr. Handly, Thank you for getting in touch, Please email us your contact information ( email and phone number, affiliation) at BD @xense.one, if you are available, we would be happy to have a video meeting and share more information about the technology and related product in the coming week. Look forward to connecting and discussing possibilities. Thank you and best, -Ying
- Q: Hello, do you have a working prototype, how does your technology compare or contrast to Nanox & Butterfly Network & do you have any direct competitors? . Hello Ying, thank you for answering my questions. Your instincts are correct. You gave me info I wanted. The analogy of gas fueled vs electric cars makes things very clear. This is an exciting new technology.
  - A: Hi, John, Thanks for asking. We will disclose exactly where we are regarding the prototype stage, ( typically there are alpha, beta and pilot prototypes ), once there is NDA signed if you are interested. we aim to submit to FDA at the end of year ( estimate) . This is a public forum, and this is a IP sensitive product / technology. Hope that you understand. Direct competitors: we are in the area of x -ray / CT imaging, so any manufacturer of such device is a potential competitor. Analogy would be auto industries with gas fueled cars vs electric cars Tesla has pioneered in. We are bringing the entire x-ray medical imaging industry into a new era. please see our pitchdeck on comparison between our technology vs existing technologies offered by market leaders in the medical imaging industry. But we think what you are really asking if there is any other company doing what we are doing, To our knowledge, we are the first company and the only company who offers this technology and we have filed 50 patents to date and the first one filed has been approved by US patent office. Can not comment too much on those companies you mentioned because for example, one of the two companies, to our knowledge, offers ultrasound based products, so have not much to do with us ( In a more generalized comparison, if you are asking, ultrasound does not have any radiation risk, however in most cases have not the resolution, nor specificity which x ray offers and are needed for front line diagnosis. Typically ultrasound imaging is a nice-to-have modality but not a must-to-have in healthcare services: for example, in stroke management or cardiac intervention guidance and or orthopedic/spine surgery guidance related applications or Emergency Room Radiology); and we do not know much about the other company nor its products. However they both are medical imaging companies and got started in the recent years and have gone through fund raising, IPO or SPAC, so we understand the interest and reason why you want to compare us to them. Please let us know if you have any other questions. Best regards, -Ying
  - A: Thank you, John, for this note.
- Q: Hello Ying, Any updates? Is the company making money yet?
- Q: Hello Ying, Any updates? Is the company making money yet?
- Q: Any Updates?
- Q: It's been 2 years and NO UPDATE Ying Zhao what is going on with the company?
  - A: Mario, Hope that you have gotten an email from us already with an update. if not, please let me know. Thank you in advance, -Ying
- Q: No updates in over a year? Anything to share?
- Q: Xense can essentially combine a x ray and ct scan/mri in one visit/procedure to get the results faster? I have noticed that doctors and insurers have been requiring more recently to first get an x ray, let the results come back, and then if needed which it usually is given said circumstances the patient then needs to schedule another visit spending more money getting an ct scan/mri. Can Xense shorten this process into one visit thus getting the results quickly? How is this unique or special to Xense though? Can't potentially in the future a patient just go directly to a ct scan/mri based on insurance/doctor agreements/health codes? And if so, wouldn't that crush the relevance of Xense?
  - A: Hi, Michael, Thank you for asking. Typically x ray imaging is more accessible while CT is less accessible in terms of proximity geographically and ease of getting to an exam. As we are providing advanced medical imaging at much lower cost through subscription, void of a capital equipment cost, most clinics including urgent care center can afford on. A patient can access advanced imaging at an urgent care center and or imaging center and or hospital, thereby improve the accessibility. Half an hour from knowing the need to exam to get to an exam and get it done vs knowing the need to exam and scheduling and make an appointment and get to an exam at an imaging center or hospital. In addition, results can be known faster these days with telehealth, if the patient no longer has the need to wait and do a second exam onsite as soon as the first exam result is known, this will save time for everyone in the healthcare delivery chain. True, this can be merely a matter of convenience for many patients. But for critical and life threatening illnesses, this could mean life and death and significant difference in quality of life. "Time is Brain" as a term coined by Neurologist , Dr. Camilo Guomez relating to stroke, Invariably most of us run into situations in our life where time to diagnosis, intervention will make a difference ( for example, 1 in 4 americans will experience a stroke episode in their life time). Good question. Thank you and best, -Ying
- Q: We want to know what you see your valuation will look like in 3 years also the income and balance statements Not to say much, I think we are very much interested in this project but then we are not opting for the crowdfunding route. We were wondering if you have provisions to accept alternative financing which should save time of WAITING SO LONG for your target to be met. With that we can cover over 50% of your target raise. Kindly reach out to me at thomas@700capital.se so we discuss further.
  - A: Thank you for this note, Thomas, we have sent you an email to the email address given. Best, -Ying
  - A: Hi Thomas, XENSE marketing specialist here. Wanted to let you know that we are on Instagram and TikTok, @xenseinc, Facebook @xense.one, and LinkedIn if you'd like to keep up with our company as we move ahead!
- Q: Hi Ying, how can one become a distributor for your product in Africa where this promises to be a major breakthrough?
  - A: Hi, Paul, Thank you for getting in touch. Please contact us at BD@xense.one, with your contact information, our marketing team will be in touch and keep you posted with our progress. Welcome your interest to work together. Many thanks for your note! Best regards, -Ying
- Q: Hi Ying, Almost 2 months later you have still raised less than $200K. Lots of startups have changed their minimum. Just send in the additional paperwork to the SEC. Yes, your current investors will need to reconfirm their investment again. I'm certain the vast majority will do that. Lower the minimum and welcome in many, many new investors who just can't commit $500 at a pop. Please consider. Thanks. Blessings
  - A: Hi, Kim , Thank you for checking and continued interest in investing in us. Unfortunately, it is a huge understaking to reconfirm and reset. Understand that we might miss some investments however, overall, it is a decision we have already made. Thank you again and best regards! -Ying